Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases S Frentzas, E Simoneau, VL Bridgeman, PB Vermeulen, S Foo, ... Nature medicine 22 (11), 1294-1302, 2016 | 411 | 2016 |
Vessel co‐option is common in human lung metastases and mediates resistance to anti‐angiogenic therapy in preclinical lung metastasis models VL Bridgeman, PB Vermeulen, S Foo, A Bilecz, F Daley, E Kostaras, ... The Journal of pathology 241 (3), 362-374, 2017 | 199 | 2017 |
Primary cilia mediate diverse kinase inhibitor resistance mechanisms in cancer AD Jenks, S Vyse, JP Wong, E Kostaras, D Keller, T Burgoyne, ... Cell reports 23 (10), 3042-3055, 2018 | 90 | 2018 |
Direct binding of Bcl-2 family proteins by quercetin triggers its pro-apoptotic activity A Primikyri, MV Chatziathanasiadou, E Karali, E Kostaras, MD Mantzaris, ... ACS chemical biology 9 (12), 2737-2741, 2014 | 79 | 2014 |
The initiator methionine tRNA drives secretion of type II collagen from stromal fibroblasts to promote tumor growth and angiogenesis CJ Clarke, TJ Berg, J Birch, D Ennis, L Mitchell, C Cloix, A Campbell, ... Current Biology 26 (6), 755-765, 2016 | 73 | 2016 |
SARA and RNF11 interact with each other and ESCRT-0 core proteins and regulate degradative EGFR trafficking E Kostaras, G Sflomos, NM Pedersen, H Stenmark, T Fotsis, C Murphy Oncogene 32 (44), 5220-5232, 2013 | 36 | 2013 |
ERBIN is a new SARA-interacting protein: competition between SARA and SMAD2 and SMAD3 for binding to ERBIN G Sflomos, E Kostaras, E Panopoulou, N Pappas, A Kyrkou, AS Politou, ... Journal of cell science 124 (19), 3209-3222, 2011 | 35 | 2011 |
Inhibitors in AKTion: ATP-competitive vs allosteric G Lazaro, E Kostaras, I Vivanco Biochemical Society Transactions 48 (3), 933-943, 2020 | 34 | 2020 |
A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity E Kostaras, T Kaserer, G Lazaro, SF Heuss, A Hussain, P Casado, ... British Journal of Cancer 123 (4), 542-555, 2020 | 32 | 2020 |
SARA and RNF11 at the crossroads of EGFR signaling and trafficking E Kostaras, NM Pedersen, H Stenmark, T Fotsis, C Murphy Methods in Enzymology 535, 225-247, 2014 | 7 | 2014 |
Embryonic stem cells are devoid of macropinocytosis, a trafficking pathway for activin A in differentiated cells N Kostopoulou, S Bellou, E Bagli, M Markou, E Kostaras, M Hyvönen, ... Journal of cell science 134 (13), jcs246892, 2021 | 5 | 2021 |
Dissecting the mechanisms of hepatocyte replacement in breast cancer liver metastases MR Nathan, L Kostaras, V Bridgeman, S Foo, P Vermeulen, A Reynolds Cancer Research 76 (14_Supplement), 4105-4105, 2016 | 1 | 2016 |
AKT supports cancer cell survival through modulation of cholesterol homeostasis I Vivanco, KN Myint, S Wallace, G Lazaro, E Kostaras, N Palaskas Cancer Research 84 (6_Supplement), 632-632, 2024 | | 2024 |
687P A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours JS de Bono, S Lord, C Yap, S Miranda, GJ Veal, K Chandran, A Paschalis, ... Annals of Oncology 34, S479-S480, 2023 | | 2023 |
Miransertib and ARQ 751 exhibit superior cell-death-inducing properties compared to other AKT inhibitors and can overcome resistance to other allosteric AKT inhibitors E Kostaras, P Cutillas, Y Yu, R Savage, B Schwartz, I Vivanco EUROPEAN JOURNAL OF CANCER 103, E143-E143, 2018 | | 2018 |
SARA and RNF11 at the Crossroads of EGFR Signaling and Trafficking T Fotsis, C Murphy Endosome Signaling Part B, 225, 2013 | | 2013 |
Decoding The BH3-Mimetic Pro-Apoptotic Activity Of Quercetin In Jurkat Cells A Primikyri, E Hatzimichael, E Karali, E Kostaras, M Manztaris, JS Shin, ... Blood 122 (21), 1672, 2013 | | 2013 |
Ο ρόλος των πρωτεϊνών του συμπλέγματος της πρωτεΐνης SARA στη μεταγωγή του σήματος και τη βιολογική δραστικότητα του TGFβ-ακτιβίνης: η πρωτεΐνη RNF11 Ε Κωσταράς Πανεπιστήμιο Ιωαννίνων. Σχολή Ιατρικής. Τμήμα Ιατρικής. Τομέας Λειτουργικός …, 2011 | | 2011 |
Erbin is a novel SARA-interacting protein on early endosomes that negatively regulates TGF-beta/Activin signaling G Sflomos, E Kostaras, E Panopoulou, N Pappas, M Hyvonen, T Fotsis, ... | | 2008 |